Chipmaker AMD has taken a 20% stake in Absci, a specialist in the use of artificial intelligence in for biologic drug discovery.

Investing.com - Morgan Stanley has initiated coverage on Absci Corp. (NASDAQ: ABSI) with an Overweight rating and a $7.00 price target. The company, currently valued at $343 million, has seen its ...

Absci Co. (NASDAQ:ABSI – Get Free Report) has received an average recommendation of “Buy” from the five ratings firms that are covering the company, Marketbeat.com reports. Five investment ...

Absci is currently developing several AI-designed pipeline programs, including ABS-101, an anti-TL1A antibody for inflammatory bowel disease with Phase 1 interim data expected later this year.

AMD CEO Lisa Su at Vox Media's Code Conference at the Ritz-Carlton Laguna Niguel, on Sept. 26, 2023, in Dana Point, Calif. She spoke at an AI developers conference in June 2025.Jerod Harris&sol ...

June 16 Cowen is doubling down on Advanced Micro Devices (NASDAQ:AMD) after the chipmaker's AI event failed to spark much excitement on Wall Street, saying the company is still laying key ...

What’s Going On: Piper Sandler analyst Harsh Kumar maintained AMD with an Overweight rating and raised its price target from $125 to $140 following the chipmaker’s pre-quarter close call.

Isomorphic Labs, a subsidiary of Alphabet Inc., is close to human trials for its AI-designed medicines. Other companies are ...

Shares of AMD rose nearly 9% on Monday after analysts at Piper Sandler raised their price target.

Venice makes a dramatic leap in processing power. The chip will support up to 256 Zen 6 cores, a 33 percent increase over the current Epyc Turin ...

The ASUS ROG Strix G16 (2025) comes in Intel and AMD flavors, and the red version of this laptop boasts impressive performance in a comfy chassis.

Xbox is partnering with AMD for its next-gen console and devices The multi-year partnership will see AMD power Xbox consoles, handhelds, PC, and Cloud.